What Is SHBG

Sex hormone binding globulin (SHBG) is a glycoprotein produced mainly by the liver that binds circulating testosterone, dihydrotestosterone (DHT), and estradiol in the bloodstream. By controlling the fraction of these hormones that remains unbound, or "free," SHBG acts as a gatekeeper determining how much active hormone reaches target tissues. Its concentration in blood is therefore as important to functional hormone status as the hormones themselves.

Conventional hormone panels often report only total testosterone or total estradiol, numbers that can mask the real picture. A man with healthy total testosterone but high SHBG may have very little free testosterone reaching muscle, bone, and brain tissue, creating a functional deficiency despite reassuring lab numbers. The reverse is also true: low SHBG can leave excess free androgens in circulation, driving unwanted effects like insulin resistance or androgenic skin and hair changes.

For longevity, SHBG intersects with several aging processes. It tracks closely with metabolic health; low SHBG is independently associated with increased risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome in large epidemiological studies. Conversely, age-related rises in SHBG contribute to the gradual decline in bioavailable testosterone that characterizes male aging. Understanding SHBG helps explain why two men with the same total testosterone number can have vastly different symptom profiles and metabolic trajectories.

The liver synthesizes SHBG and releases it into the bloodstream. Production is stimulated by estrogen and thyroid hormone and suppressed by insulin, androgens, and growth hormone. This is why conditions of high insulin output (obesity, metabolic syndrome) tend to lower SHBG, while lean, insulin-sensitive physiology or hyperthyroidism tends to raise it.

Once in circulation, SHBG binds sex steroids with differing affinities. It has the highest affinity for DHT, followed by testosterone, and a much lower affinity for estradiol. Only about 1 to 3 percent of testosterone circulates truly free; roughly 30 to 45 percent is loosely bound to albumin (and considered bioavailable), while the remaining 50 to 65 percent is tightly bound to SHBG and largely unavailable for tissue uptake. When SHBG rises, the balance shifts so that a greater share of total testosterone is sequestered, leaving less to act at androgen receptors in muscle, bone, the nervous system, and reproductive organs.

SHBG also appears to have direct cellular effects beyond its carrier role. Research has identified an SHBG receptor on cell membranes that, when activated by steroid-loaded SHBG, triggers intracellular cyclic AMP signaling. This means SHBG is not merely a passive shuttle; it may modulate how tissues respond to hormones at the receptor level, though this area of biology is still being clarified.

SHBG sits at the intersection of the hypothalamic-pituitary-gonadal axis and hepatic metabolism. The liver adjusts SHBG production in response to circulating estrogen (which increases it), insulin (which decreases it), thyroid hormone (which increases it), and androgens (which decrease it). This creates a dynamic feedback loop: as testosterone falls with age and estrogen often rises relative to it, SHBG tends to climb, further reducing free testosterone. The net effect is a steeper functional decline in androgen signaling than total testosterone numbers alone would suggest.

In clinical practice, SHBG is essential for interpreting testosterone replacement therapy. Exogenous testosterone can suppress SHBG, inflating free testosterone levels beyond what the total dose would predict. Conversely, medications like clomiphene citrate, which raise endogenous testosterone through LH stimulation, sometimes also raise SHBG, partially offsetting the gains in total testosterone. Understanding these dynamics prevents the common mistake of adjusting therapy based solely on total testosterone readings.

SHBG also binds estradiol, though with lower affinity. In men, this matters because estradiol has its own set of physiological roles, including bone maintenance, cardiovascular protection, and cognitive function. A major shift in SHBG changes the free fraction of both androgens and estrogens simultaneously, altering the overall hormonal milieu in ways that cannot be captured by looking at any single hormone.

Elevated SHBG in men can produce symptoms that overlap with classic low testosterone: fatigue, reduced libido, difficulty gaining or maintaining muscle mass, depressed mood, and cognitive sluggishness. The distinguishing feature is that total testosterone on bloodwork may appear normal or even robust, leading clinicians to dismiss a hormonal contribution to the symptoms.

Low SHBG often accompanies a different symptom cluster tied to metabolic dysfunction. Increased waist circumference, rising fasting glucose, elevated triglycerides, and skin changes such as acne or oily skin may be present. In some men, low SHBG with correspondingly high free testosterone can still coexist with poor subjective well-being if the underlying driver is insulin resistance and systemic inflammation.

Physical signs are not specific enough for diagnosis, which is why lab testing is necessary. However, a pattern of worsening body composition despite consistent training, or persistent fatigue that does not respond to sleep and stress interventions, should prompt a clinician to measure SHBG alongside a full sex hormone panel rather than relying on total testosterone alone.

There is no medication approved specifically to raise or lower SHBG, so management centers on addressing the conditions that drive it out of range. For low SHBG caused by insulin resistance and excess adiposity, the most effective approach is metabolic rehabilitation: reducing refined carbohydrate intake, building lean mass through resistance training, improving sleep, and achieving a healthier body composition. These interventions tend to raise SHBG gradually as insulin levels normalize.

For elevated SHBG, clinicians first rule out hyperthyroidism, liver disease, and medication effects. When high SHBG is causing functional androgen deficiency (confirmed by low calculated free testosterone and consistent symptoms), testosterone replacement therapy is one option. Some practitioners use low-dose boron supplementation, which preliminary studies suggest may modestly reduce SHBG, though the evidence base is small. Others use medications like low-dose oxandrolone or danazol in specific clinical contexts, though these carry their own risk profiles.

A subtler but important approach is dietary protein adequacy. Very low caloric intake or very low carbohydrate diets sustained over time can elevate SHBG, and simply ensuring sufficient energy and macronutrient intake may bring levels back to a functional range. The key principle is that SHBG responds to the metabolic environment, so shifting that environment is more durable than chasing the number with a single supplement or drug.

Large epidemiological studies, including data from the Framingham Heart Study and the European Male Ageing Study, have consistently linked low SHBG to increased risk of type 2 diabetes and metabolic syndrome, independent of testosterone and obesity. Several prospective cohort analyses have found that low SHBG predicts incident diabetes years before glucose levels become abnormal, suggesting it may serve as an early metabolic biomarker. The association between low SHBG and cardiovascular disease has also been reported, though the directionality and independence of this relationship from insulin resistance remain debated.

Mechanistic research on the SHBG membrane receptor and its intracellular signaling is still in earlier stages, with most data coming from cell culture and animal models. Whether manipulating SHBG directly (rather than addressing its upstream drivers) produces independent health benefits is not established. Clinical guidelines for testosterone therapy increasingly recommend measuring SHBG to calculate free testosterone, but there is no consensus on optimal SHBG ranges, and reference intervals vary across laboratories and assay methods. The field would benefit from interventional trials that track SHBG alongside hard clinical endpoints rather than relying on observational associations alone.

SHBG is a biomarker, not a therapy, so the risks lie in misinterpretation rather than side effects. Treating SHBG levels in isolation, for instance aggressively using supplements or medications to lower high SHBG without understanding why it is elevated, can mask underlying conditions like thyroid disease or liver pathology. Reference ranges for SHBG are broad and vary by age, sex, and assay platform, so a single value out of range does not necessarily indicate dysfunction. Decisions about hormone therapy should integrate SHBG with free testosterone, symptoms, and metabolic context, not rely on any single number.